Publicacións en colaboración con investigadores/as de Hospital del Mar (36)

2023

  1. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants

    Nature Genetics, Vol. 55, Núm. 12, pp. 2065-2074

  2. Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry

    American Journal of Human Genetics, Vol. 110, Núm. 7, pp. 1200-1206

2022

  1. Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score

    Prostate cancer and prostatic diseases, Vol. 25, Núm. 4, pp. 755-761

2021

  1. Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer

    Prostate Cancer and Prostatic Diseases, Vol. 24, Núm. 2, pp. 532-541

  2. Polygenic hazard score is associated with prostate cancer in multi-ethnic populations

    Nature Communications, Vol. 12, Núm. 1

  3. Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (Nature Genetics, (2021), 53, 1, (65-75), 10.1038/s41588-020-00748-0)

    Nature Genetics

  4. Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECP-SEOR Study

    Journal of Clinical Oncology, Vol. 39, Núm. 28, pp. 3118-3127

  5. Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction

    Nature Genetics, Vol. 53, Núm. 1, pp. 65-75

2020

  1. An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk

    Nature Communications, Vol. 11, Núm. 1

  2. Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan

    Nature Communications, Vol. 11, Núm. 1

  3. High-dose neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery in potentially-resectable stage IIIA-N2 NSCLC. A multi-institutional retrospective study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)

    Reports of Practical Oncology and Radiotherapy, Vol. 25, Núm. 3, pp. 447-455

  4. The CHEK2 variant C.349A>G is associated with prostate cancer risk and carriers share a common ancestor

    Cancers, Vol. 12, Núm. 11, pp. 1-17

2019

  1. Are there enough radiation oncologists to lead the new Spanish radiotherapy?

    Clinical and Translational Oncology, Vol. 21, Núm. 12, pp. 1663-1672

  2. Association analyses identify 31 new risk loci for colorectal cancer susceptibility

    Nature Communications, Vol. 10, Núm. 1

  3. Circulating metabolic biomarkers of screen-detected prostate cancer in the ProtecT study

    Cancer Epidemiology Biomarkers and Prevention, Vol. 28, Núm. 1, pp. 208-216

  4. Correction to: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (Nature Genetics, (2018), 50, 7, (928-936), 10.1038/s41588-018-0142-8)

    Nature Genetics

  5. Erratum to: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia (Nature Communications, (2018), 9, 1, (1340), 10.1038/s41467-018-03178-z)

    Nature Communications

  6. Erratum to: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility (Nature Communications, (2017), 8, 1, (1892), 10.1038/s41467-017-00320-1)

    Nature Communications

  7. Erratum to: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (Nature Communications, (2018), 9, 1, (4616), 10.1038/s41467-018-06863-1)

    Nature Communications

  8. Erratum to: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (Nature Communications, (2018), 9, 1, (3707), 10.1038/s41467-018-04989-w)

    Nature Communications